Posts tagged ProMIS
ProMIS releases clinical results at Alzheimer’s conference

ProMIS Neurosciences (TSX:PMN) released results in two presentations of its recent therapeutic developments at the Alzheimer’s Association International Conference in Toronto.

“Our results presented at the AAIC meeting indicate that multiple monoclonal antibodies (mAbs) directed against five novel AD targets are viable therapeutic candidates, as they showed selective binding to the oligomeric forms of Amyloid beta, with little or no binding to Amyloid beta monomer,” CSO, Neil Cashman, said in a statement.

Read More
ProMIS names Johanne Kaplan as CDO

ProMIS Neurosciences (TSX:PMN) has appointed Johanne Kaplan to the post of chief development officer to focus on supporting the design and execution of the company’s development programs and partnering efforts.

Read More
ProMIS in new program to identify ALS targets

ProMIS Neurosciences (TSX:PMN) has initiated a program to identify novel therapeutic targets on neurotoxic strains of the protein TDP43, which is implicated in the development of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

“ProMIS will apply its proprietary computational algorithms, supplemented by other methods pioneered by ProMIS scientists, to identify specific therapeutic targets on misfolded TDP43,” SCO, Dr. Neil Cashman, said in a statement.

Read More